Valuation: Rapport Therapeutics, Inc.

Capitalization 576M 556M 525M 463M 824M 49.96B 914M 6.25B 2.32B 20.76B 2.16B 2.11B 87.66B P/E ratio 2024 *
-4.25x
P/E ratio 2025 * -4.81x
Enterprise value 276M 267M 252M 222M 395M 23.93B 438M 3B 1.11B 9.94B 1.03B 1.01B 42B EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
93.46%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-4.20%
1 week-11.45%
Current month-4.08%
1 month+6.28%
3 months-41.49%
6 months-17.42%
Current year-11.27%
More quotes
1 week
15.57
Extreme 15.57
18.06
1 month
12.09
Extreme 12.0948
18.27
Current year
12.09
Extreme 12.0948
19.75
1 year
12.09
Extreme 12.0948
29.74
3 years
12.09
Extreme 12.0948
29.74
5 years
12.09
Extreme 12.0948
29.74
10 years
12.09
Extreme 12.0948
29.74
More quotes
Director TitleAgeSince
Chief Tech/Sci/R&D Officer 60 2022-12-31
Chief Executive Officer 47 2023-01-31
Director of Finance/CFO 57 2023-10-31
Manager TitleAgeSince
Director/Board Member 60 2023-08-22
Director/Board Member 47 2023-02-28
Director/Board Member 53 2022-01-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-4.20%-11.45% - - 601M
+0.59%+0.46%+36.99%-0.85% 48.01B
-2.94%+0.42%-7.93%-17.76% 36.45B
+0.39%+1.30%+5.06%+23.81% 26.18B
-1.83%-3.06%-32.72%-28.37% 15.76B
+2.22%-0.03%+66.39%+73.56% 15.43B
-2.95%-9.48%-64.62%-80.83% 12.26B
-2.25%-5.80%+0.57%-34.69% 11.05B
-7.52%-5.51%+0.45%+87.46% 10.99B
+4.17%+15.13% - - 10.76B
Average -1.48%-1.93%+0.52%+2.79% 18.75B
Weighted average by Cap. -0.89%+0.13%+7.65%+1.19%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -81.73M -78.99M -74.57M -65.79M -117M -7.09B -130M -888M -329M -2.95B -306M -300M -12.44B -129M -125M -118M -104M -185M -11.23B -205M -1.41B -522M -4.66B -485M -475M -19.7B
Net Debt -300M -290M -274M -241M -429M -26.02B -476M -3.26B -1.21B -10.81B -1.12B -1.1B -45.66B -378M -365M -345M -304M -541M -32.81B -600M -4.11B -1.52B -13.63B -1.42B -1.39B -57.57B
More financial data * Estimated data
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a portfolio of precision small molecule product candidates. The Company focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. It advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
Employees
-
More about the company
Date Price Change Volume
25-02-11 15.74 $ -4.20% 116,029
25-02-10 16.43 $ +1.86% 58,252
25-02-07 16.13 $ -3.70% 113,071
25-02-06 16.75 $ -4.56% 69,615
25-02-05 17.55 $ -1.27% 65,928

Delayed Quote Nasdaq, February 11, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.74USD
Average target price
37.33USD
Spread / Average Target
+137.19%
Consensus

Quarterly revenue - Rate of surprise